

Table 1: Factors implicated as angiogenic promoters and inhibitors in prostate, bladder and kidney cancers

Cancer	Promoter	Inhibitor	
Prostate	Basic fibroblast growth factor (bFGF)	Endogenous inhibitor Interleukin-10 (IL-10)	
	Vascular endothelial growth factor (VEGF)	Tissue inhibitor of metalloproteinase-1 Angiostatin	
	Interleukin-8 (IL-8)	Prostate-specific antigen	
	Matrix metalloproteinase-9 (MMP-9)	Interferon	
	Matrix metalloproteinase-2 (MMP-2)	Pharmaceutical agent Anti-VEGF antibody (A4.6.1)	
	Transforming growth factor- β_1	Fumagillin analogue, O-(chloroacetyl-carbamoyl) fumagillol (TNP-470)	
	Platelet-derived endothelial growth factor	Linomide Carboxyamido-triazole	
	Nitric oxide	Diet Energy-reduced diet Soy products	
	Bladder	bFGF	Endogenous inhibitor Thrombospondin
		VEGF	Interferon
Midkine		Pharmaceutical agent Antiepidermal growth factor receptor antibody (C225)	
Thymidine phosphorylase		DC101	
Hepatocyte growth factor		Halofuginone	
Hyaluronic acid fragments		Diet Soy products	
IL-8			
Transforming growth factor- β_1			
Hyaluronidase			
MMP-9			
Angiogenin			
Kidney	bFGF	Endogenous inhibitor Endostatin	
	VEGF	Interferon	
	Thymidine phosphorylase	Vitamin D ₃	
	MMPs	Pharmaceutical agent Fumagillin analogue, O-(chloroacetyl-carbamoyl) fumagillol (TNP-470)	
	Urokinase-type plasminogen activator (uPA)		
	Transforming growth factor- β_1		
	Hepatocyte growth factor		

[\[Return to text\]](#)